Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Beijing Obstetrics and Gynecology Hospital Capital Medical University, Beijing, Beijing Municipality Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Harbin Medical University Cancer Hospital, Harbin, Heilongjiang